We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B‐cell acute lymphoblastic leukaemia in children.
- Authors
Sutton, Rosemary; Venn, Nicola C.; Law, Tamara; Boer, Judith M.; Trahair, Toby N.; Ng, Anthea; Den Boer, Monique L.; Dissanayake, Anuruddhika; Giles, Jodie E.; Dalzell, Pauline; Mayoh, Chelsea; Barbaric, Draga; Revesz, Tamas; Alvaro, Frank; Pieters, Rob; Haber, Michelle; Norris, Murray D.; Schrappe, Martin; Dalla Pozza, Luciano; Marshall, Glenn M.
- Abstract
Summary: To prevent relapse, high risk paediatric acute lymphoblastic leukaemia (ALL) is treated very intensively. However, most patients who eventually relapse have standard or medium risk ALL with low minimal residual disease (MRD) levels. We analysed recurrent microdeletions and other clinical prognostic factors in a cohort of 475 uniformly treated non‐high risk precursor B‐cell ALL patients with the aim of better predicting relapse and refining risk stratification. Lower relapse‐free survival at 7 years (RFS) was associated with <italic>IKZF1</italic> intragenic deletions (<italic>P</italic> < 0·0001); <italic>P2RY8</italic>‐<italic>CRLF2</italic> gene fusion (<italic>P</italic> < 0·0004); Day 33 MRD>5 × 10−5 (<italic>P</italic> < 0·0001) and High National Cancer Institute (NCI) risk (<italic>P</italic> < 0·0001). We created a predictive model based on a risk score (RS) for deletions, MRD and NCI risk, extending from an RS of 0 (RS0) for patients with no unfavourable factors to RS2 + for patients with 2 or 3 high risk factors. RS0, RS1, and RS2 + groups had RFS of 93%, 78% and 49%, respectively, and overall survival (OS) of 99%, 91% and 71%. The RS provided greater discrimination than MRD‐based risk stratification into standard (89% RFS, 96% OS) and medium risk groups (79% RFS, 91% OS). We conclude that this RS may enable better early therapeutic stratification and thus improve cure rates for childhood ALL.
- Subjects
LYMPHOBLASTIC leukemia in children; LEUKEMIA in children; DISEASE relapse prevention; B cells; JUVENILE diseases
- Publication
British Journal of Haematology, 2018, Vol 180, Issue 4, p550
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.15056